Shares of Affymax Inc. have yet to recover from the beating they took about a year ago when Phase III data for peginesatide (formerly Hematide) fell short of investor expectations, but that hasn't stopped the Palo Alto, Calif.-based biotech and partner Takeda Pharmaceutical Co. Ltd. from moving forward with a new drug application (NDA).